NCT02695628View on ClinicalTrials.gov

[18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

September 13, 2016

Primary Completion Date

April 30, 2018

Study Completion Date

October 31, 2018

Conditions
Adult Liver CarcinomaLiver Cirrhosis
Interventions
DRUG

18F-Fluoromisonidazole

Undergo \[18F\] FMISO PET/CT

PROCEDURE

Arterial Embolization

Undergo transcatheter arterial embolization

DIAGNOSTIC_TEST

Computed Tomography

Undergo \[18F\] FMISO PET/CT

DIAGNOSTIC_TEST

Positron Emission Tomography

Undergo \[18F\] FMISO PET/CT

Trial Locations (1)

94304

VA Palo Alto Healthcare System, Palo Alto

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Stanford University

OTHER

NCT02695628 - [18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer | Biotech Hunter | Biotech Hunter